ITEX

Inhibitex was a clinical-stage biopharmaceutical company focused on developing differentiated anti-infective products for the treatment and prevention of serious infectious diseases. The company's lead programs included INX-189, a potent nucleotide polymerase inhibitor for chronic hepatitis C, and tefibazumab (Aurexis), a humanized monoclonal antibody for serious Staphylococcus aureus infections. Inhibitex was notably acquired by Bristol-Myers Squibb in 2012 for approximately $2.5 billion, primarily for its promising hepatitis C pipeline. However, the lead drug candidate was later discontinued due to safety concerns, marking a significant event in biotech M&A history.